ScripAnticipating more hardships ahead, innovative drug makers are taking to the road and talking with potential investors from some non-conventional sectors, noted executives at the inaugural Asia Bio Par
ScripBig backing for venture capital-funded private biopharmaceutical companies has not wavered as 2021 draws to a close despite a recent slowdown in large initial public offerings by drug developers in th